TP - Unfortuntely PRM has mostly delivered disappointment in recent years, BUT at least the 7p target is double the SP now! I am not sure how they arrive at 7p! Anyway, lets hope Haigh can deliver something positive soon to at least double the SP!!! ATB AR
Well PRM was pretty central to my reappraisal of my approach to stocks and investing, and I sold at an 18K loss (!) way back..... I would now be nearly £25K down (near total wipe out for my holding!), and I would also have suffered the way many other LTH's have, hoping and praying that PRM could revive.... It must have been one of the worst performers in the Bio Sector over a long period, short of just going bust! The story isnt over yet, and there is always the outside chance it will recover some of its glory ..... BUT its been a long slug... and you just have to hope Haigh has seen some potential that the market has missed..... although he has now been in post for quite a while now and no sign of recovery at all. I just hope that he can revive PRM, and that next results offer some hope to very long suffering holders - ATB AR
I wonder if anyone remembers the days when PRM were going to inoculate every cow in the world with their wonderful markers thus ensuring a lively retirement for us all! No didn't happen but the then finance director made a packet as the sp rocketer to nearly £3, Alas I didn't sell.
Prm has been promising much & delivering wet FA for 20 years ,so,a bit like the boy who cried wolf ,maybe one day we will truly surprise The Market with truly groundbreaking news & my legacy to my kids (& 1 day maybe grandkids) will be Prm shares with some value-but I continue to not hold my breath .
I also recently read an article on Sepsis, where biomarkers were found to give the best indication of the presence of this illness.
I suppose that the SP Is unaffected by these news items, because many investors do not understand the possible implications, and those that do, are awaiting for news of profitability (promised in 2018).
This present news headline sounds like it depends on proteomics tests as well as genetic tests.
I would think this could have significant impact on proteomic testing sales and services/ Why is this not affecting PRM share price??
Interims on March 28th last year (SP High 4.19p - low 4p - and its marginally lower now!) were reasonable, but, as I said, the SP has merely reflected a lot of the disappointment PRM has suffered over recent years, and has travelled sideways for a few months!
The BIG Q is whether PRM can revive hope, and its fortunes, with its next guidance in March 2018, or has Haigh made a duff pick? I must say its imossible to say, BUT IF PRM can show signs of life and progress, any positive move in the SP should be reasonably substantial.... sentiment IS a funny old thing!
Meanwhile.... everything is opaque as it can be.... and I am not going to risk a penny with PRM, unless a reasonable low is hit.... I watch with interest, and hope LTHs have a good Christmas break! ATB AR
...since the end of June.... and nothing has shifted the SP much! Surely Haigh must have some deal/product to shift the SP with an RNS?! Still too much of a gamble for me! But I am a bit tempted..... Oh well, lets hope long suffering holders geet some joy after so long a wait. Best of LUCK to all - AR
In 2012 we announced a collaboration regarding our Biomarkers for use in studies into HD-which I presume came to nothing & we have no interest in the wonderful news yesterday-which is a pity.Had we been involved I would have expected a more positive SP reaction !
G5 - I was aware that Diggle is investing for a fund, BUT all my comments still apply IF PRM can rehabilitate itself - lets hope some good news isnt too far off for PRM - its been a long time in the wilderness! ATB AR
'Martin Diggle, Non Executive Director, bought 184,460 shares in the company on the 25th October 2017 at a price of 3.18p. The Director now holds 55,197,431 shares'. Thata hell of a lot of shares... and belief in PRM... Lets hope he isnt too close to PRM to see clearly whats goig on, BUT if PRM does recover, and sentiment improve towards PRM, he will have made a brilliant call.
A little too risky for me.... but things seem to have been very quiet with PRM recently, so lets hope Diggle's belief in PRM is right! AR
PS - I cant remember when Haigh and Diggle joined the board, BUT PRM seems intent on testing new lows, and their influence SO FAR hasnt had the desired effect.
Yes it was 175p (roughy) in late Decemner 2003, Ah the good old days!!! Sentiment has certainy taken a hit (understandably - given the poor performance and lack of revenues!), BUT hopefully Haigh can steer PRM back onto a clearer path, and back to more stable conditions and revemues - sentiment is a funny old thing, and frequently gets way ahead of its self! BUT twas ever thus... AR
Take a look at the shorter 6 month graph for PRM. The 200 day SMA is beginning to slow, and the trend looks quite promising.
As we get into the final quarter of 2017, we should expect further news of PRM's admitttedly slow breakeven, through to profitabiity in 2018.
In 2019 income stream from Sandoz should be coming through (if all goes well), and meanwhile the progress being made through Thermo Fisher is well documented.
B'mango - hope you do well, and any glimps at the long term chart is a slutory experience (!) - one can only hope that PRM is at last on the turn (but waiting confirmation in my books)! Its amasing to think that the SP got to over 130p in (was it) 2007?! Haigh is certainly an encouraging move, and one can only hope Pearce has at last learnt something about the need for 'delivery' over and above endless bullishness! Hopefully Haigh has sorted that issue out at last! Other new appointments seem to offer more hope for better times too... but as ever I wait for a bit more confirmation that a better SP is likely. ATB AR
1. TMT sales showed a nice increase. Unfortunately there seems to be a warning in the CEOs statement that the company runs at full capacity in TMT synthesis, plus relevant reagents may not be available to them. So the delay of higher plexing is already announced, and maybe the company can not deliver the (growing) amounts the market wants to buy.
2. In contrast, revenues for "biomarker business" is a meager 400k, of which 100k are a one-time payment for the stroke license. This means that "proteoshop" or biomarker collaborations with pharma actually went down. No mentioning of the seasoned 2 Mio deal with this Alzheimer company TauRx.
3. Aiming at cGLP certification suggests that ISO is not enough. "Mass specs running at full capacity" (not this statement but not too long ago) and 300k revenue @ half year?
That looks really grim.
So in summary:
TMT business seems profitable and with good growth potential, but limited in work force
Service business does not get traction, loss leader. Much too expensive. And pharma can go many places to get (TMT-based) Mass spec service. Anyone who thinks it is necessary can buy the stuff. No USP for proteome!!!
Conclusion: Concentrate on TMT. Stop wasting money in pharma service business.
Do what you do best: TMT and innovations in higher plexing. This might make the co profitable by end of the year. Get rid of all personell in pharma services. They eat what you harvest with TMT...
Being something of a chart fanatic, Andy, would you say a rise from here might confirm a bullish double bottom formation, or is the length of time between the two troughs too long?
Agree that there are some signs of recovery here, but it will need tangible evidence in the form of new contracts as we have had all the talk and promise now and the market needs more than just that. Am very impressed with focus and determination of new management, wish Haigh had been at the helm some years ago and then maybe we wouldn't be looking at such a lowly market cap now. In hindsight, it rather looks as if CJP was simply hoping big pharma would come to him and all he needed to do in the meantime was file and maintain as many patents as he could.
Richard Dennis sounds a far more impressive sales guy then the company have had hitherto, hope he will aggressively go out and do the deals.
3.5p support was last hit in early March this year - a break below would be bad news as the SP would literally be in uncharted territory - selling pressure has eased a fair bit, BUT 3.5p REALLY needs to hold. AR
C1 - goodness thats some disappointment with results today, and any suggestion of a fund raising isnt going to help the SP shorter term - very disappointing, but that seems to be what PRM does. Its not good and will take time to recover - lets hope the new strategy (CEO) starts to show some hope the way back to the SP - It took OXB quite a while to recover, and its prospects look much improved. (I would certainly have done much better to hang on there, and hold... BUT thats life. Lets hope I get another chance with OXB, and I can buy back on any weakness IF it happens - Oh well, such is investing), but a least I have a very useful amount of cash to put back to work in the market.... and I do like to hold a good amount of cash at times, even if I get my sells and buys wrong at times..... To err is alas all too human, BUT as long as I am making some money the challenge is very enjoyable.... and long term performance is very important to me.
ATB to all holders... and hopefully PRM will turn around sometime soon.... it seems to be getting there (despite todays disappointment!), especially with a new CEO at the helm. AR
My remark that referred to "realism" was meant to point out that the milestone payment would only be a fraction of the "real" value to PRM, should the stroke test become an industry standard.
Having been duped by CP on many occasions, long-term investors in PRM must be hoping that the rather short statement issued by the new team tends to underestimate the potential.
In fact, I was surprised that there was no mention whatsoever of future income. After CP's hyperbole, PRM statements have been factual. However it now looks as though they could use some better PR, a point that I have made before!
I always try to keep it real, but I remain as ever an optimist!
TP - well 'realism' is a funny old thing, but I would b down by £24,564 (30K PM @ 80p (I think it was) IF I had just hung on being 'realistic'. I have a feeling that PRM 'may be' on the turn at last, (as 'every dog has his day' (well sometimes!!)).
These Bios are a tough call, but hopefully some of that 'positive vibe' can return to the SP soon... its getting there (as it is more or less in oversold territory!) AR
That 'key' 200 day EMA is nearly double the current SP... SO quite some way before the SP is in more confident territory, BUT hope and realism are rather open to interpretation I feel! Keep t real! ATB AR
Although the Randox milestones will be useful, the real money comes with the royalty payments in the double digits. We will see all the big global diagnostics companies license the Stoke biomarkers from Proteome Sciences, as they will require a Stroke assay on their own lab. testing platforms. The global market for a Stroke blood test is valued at $500 million to $1 billion a year. With PRM receiving a minimum of 10% of that, the current sp of 4.5p looks ridiculous.
D297 - well a bit of positive news at last, and it saved the SP, which for the previous 2 days has sat on a downtrend - hopefully a better SP will be in the offing soon! Good news has been thin on the ground for PRM, but it may well be a case of 'every dog.... etc" So I will have a good strategic think over the weekend, and whether its a good idea to take on a bit more risk in the portfolio... Hope all goes well - AR
After all these years of hope & aspiration we long term investors have,at very very very long last,been rewarded by a milestone payment of £100k & I can hardly contain my excitement.
It may lead to great things & my ,as yet unborn,grandchildren,may,one day benefit from my shrewd investment here,almost 20years ago !
TP - well the SP has come back to 'sit on' a downtrend - you can only hope the downtrend holds as a retest of 4.5p sipport 'may be' on the cards if not, but not guaranteed of course! Its all down to sentiment, but of course IF PRM can start to recover (and it has had a hell of a tough time!) it could attract a lot of folks who see PRM as a good recovery play - its always a possibility - so lets hope PRM can deliver on its promise. ATB AR
Important message from the Financial Conduct Authority:
Posting inside information that is not public knowledge, or information that is false or misleading, may constitute market abuse.
This could lead to an unlimited fine and up to seven years in prison.
If you have any information, concerns or queries about market abuse, click here.
The content of the messages posted represents the opinions of the author, and does not represent the opinions of Interactive Investor Trading Limited or its affiliates and has not been approved or issued by Interactive Investor Trading Limited.
You should be aware that the other participants of the above discussion group are strangers to you and may make statements which may be misleading, deceptive or wrong.
Please remember that the value of investments or income from them may go down as well as up and that the past performance of an investment is not a guide to its performance in the future.
The discussion boards on this site are intended to be an information sharing forum and is not intended to address your particular requirements.
Whilst information provided on them can help with your investment research you need to consider carefully whether you should make (or refraining from making) investment or other decisions based on what you see without doing further research on investments you are interested in.
Participating in this forum cannot be a substitute for obtaining advice from an appropriate expert independent adviser who takes into account your circumstances and specific investment needs in selected investments that are appropriate for you.